| Literature DB >> 28532395 |
Lijuan Zhang1,2, Jing Wang3, Qiuxiang Zhang1,2, Ting Fu1,2, Rulan Yin1,2, Ze Wang3, Liren Li2, Xianhua Wu4, Zhifeng Gu5.
Abstract
BACKGROUND: There have been no previous report of hand joint destruction prevalence in Chinese rheumatoid arthritis (RA) patients. Therefore, the aim of this study was to investigate the prevalence and potential factors of hand joint destruction among RA patients from Nantong China. In addition, we wanted to examine the differences between functional capacity, psychological status, and quality of life in patients with hand joint destruction compared to those without hand joint destruction.Entities:
Keywords: Disease activity; Hand joint destruction; Quality of life; Rheumatoid arthritis
Mesh:
Year: 2017 PMID: 28532395 PMCID: PMC5440941 DOI: 10.1186/s12891-017-1548-7
Source DB: PubMed Journal: BMC Musculoskelet Disord ISSN: 1471-2474 Impact factor: 2.362
Fig. 1“Flow chart of the study”
Differences between demographic and clinical variables in patients with hand joint destruction compared to those without hand joint destruction
| Variables | Overall sample | Non-hand joint destruction (Sharp score = 0; | Hand joint destruction |
|
|
|---|---|---|---|---|---|
| Demographic factors | |||||
| Female gender, no. (%) | 135 (83.9) | 69 (81.2) | 66 (86.8) | 0.95* | 0.329 |
| Age, mean (SD) years | 53.7 (12.9) | 52.7 (13.7) | 54.8 (12.1) | −1.03** | 0.303 |
| BMI, mean (SD) kg/m2 | 22.0 (3.4) | 22.3 (3.3) | 21.6 (3.5) | −1.29** | 0.198 |
| Education, years, no. (%) | 5.58* | 0.018 | |||
| ≤ 9 years | 122 (75.8) | 58 (68.2) | 64 (84.2) | ||
| > 9 years | 39 (24.2) | 27 (31.8) | 12 (15.8) | ||
| Employment status, no. (%) | 0.01* | 0.946 | |||
| Employed | 97 (60.2) | 51 (60) | 46 (60.5) | ||
| Unemployed | 64 (39.8) | 34 (40) | 30 (39.5) | ||
| Income/person/month, USD, no. (%) | 0.28* | 0.599 | |||
| ≤ 435 USD | 144 (89.4) | 75 (88.2) | 69 (90.8) | ||
| > 435 USD | 17 (10.6) | 10 (11.8) | 7 (9.2) | ||
| Personal health insurance, no. (%) | 0.07* | 0.785 | |||
| Yes | 117 (72.7) | 61 (71.8) | 56 (73.7) | ||
| No | 44 (27.3) | 24 (28.2) | 20 (26.3) | ||
| Tobacco usage, no. (%) | 2.42* | 0.120 | |||
| Yes | 17 (10.6) | 12 (14.1) | 5 (6.6) | ||
| No | 144 (89.4) | 73 (85.9) | 71 (93.4) | ||
| Alcohol usage, no. (%) | 1.66* | 0.197 | |||
| Yes | 23 (14.3) | 15 (17.6) | 8 (10.6) | ||
| No | 138 (85.7) | 70 (82.4) | 68 (89.4) | ||
| Clinical factors | |||||
| Comorbidities, yes, no. (%) | 2.34* | 0.127 | |||
| Yes | 34 (21.1) | 14 (16.5) | 20 (26.3) | ||
| No | 127 (78.9) | 71 (83.5) | 56 (73.7) | ||
| Disease duration, median (IQR) years | 4.1 (9) | 2 (4.5) | 9.5 (13.5) | −6.64 | <0.001 |
| VAS pain (range 0–10), median (IQR) | 5 (6) | 3 (6) | 5 (6.5) | −1.05 | 0.294 |
| DAS28-ESR, median (IQR) | 3.3 (1.7) | 2.9 (1.6) | 3.6 (1.8) | −3.35 | 0.001 |
| DMARDs usage, no. (%) | 4.98* | 0.026 | |||
| Yes | 152 (94.4) | 77 (90.6) | 75 (98.7) | ||
| No | 9 (5.6) | 8 (9.4) | 1 (1.3) | ||
| Corticosteroids usage, no. (%) | 9.32* | 0.002 | |||
| Yes | 92 (57.1) | 39 (45.9) | 53 (69.7) | ||
| No | 69 (42.9) | 46 (54.1) | 23 (30.3) | ||
| Biologics usage, no. (%) | 0.02* | 0.889 | |||
| Yes | 11 (6.8) | 3 (3.5) | 3 (3.9) | ||
| No | 150 (93.2) | 82 (96.5) | 73 (96.1) | ||
| ESR, median (IQR) mm/h | 22 (38) | 20 (35.5) | 23.5 (50.5) | −0.90 | 0.367 |
| CRP, median (IQR) mg/l | 7.5 (12.4) | 5.9 (13.6) | 8.2 (20.6) | −1.60 | 0.110 |
| RF positive, no. (%) | 12.68* | <0.001 | |||
| Yes | 109 (67.7) | 47 (55.3) | 62 (81.9) | ||
| No | 52 (32.3) | 38 (44.7) | 14 (18.1) | ||
| Anti-CCP antibody positive, no. (%) | 15.45* | <0.001 | |||
| Yes | 104 (64.6) | 43 (50.6) | 61 (80.3) | ||
| No | 57 (35.4) | 42 (49.4) | 15 (19.7) | ||
IQR Interquartile range, BMI body mass index, VAS visual analog scale, DAS28 Disease Activity Score in 28 joints, DMARDs disease-modifying antirheumatic drugs, ESR erythrocyte sedimentation rate, CRP C-reactive protein, RF rheumatoid factor, Anti-CCP anti-cyclic citrullinated peptide
*Chi-square test
**Independent t-tests
Results of multivariate analysis using backward stepwise logistic regression model in patients with hand joint destruction
| Variables | B | SE | Wald | OR | OR 95% CI |
| ||
|---|---|---|---|---|---|---|---|---|
| Lower bound | Upper bound | |||||||
| Step 1 | Education ≤ 9 years | 1.11 | 0.54 | 4.26 | 3.01 | 1.16 | 7.64 | 0.038 |
| Disease duration, years | 0.18 | 0.05 | 20.37 | 1.22 | 1.13 | 1.51 | <0.001 | |
| DAS28-ESR | 0.39 | 0.16 | 5.30 | 1.46 | 1.06 | 2.15 | 0.022 | |
| DMARDs usage, yes | −2.24 | 1.28 | 3.11 | 0.13 | 0.04 | 1.37 | 0.077 | |
| Corticosteroids usage, yes | −0.76 | 0.45 | 3.06 | 0.48 | 0.21 | 1.09 | 0.080 | |
| RF positive, yes | −0.66 | 0.39 | 2.79 | 0.63 | 0.13 | 1.74 | 0.095 | |
| Anti-CCP antibody positive, yes | −0.97 | 0.46 | 5.02 | 1.03 | 0.17 | 1.57 | 0.025 | |
| R2 | 0.380 | |||||||
| Step 2 | Education ≤ 9 years | 1.11 | 0.55 | 4.24 | 3.06 | 1.1 | 8.41 | 0.041 |
| Disease duration, years | 0.20 | 0.05 | 21.26 | 1.21 | 1.12 | 1.32 | <0.001 | |
| DAS28-ESR | 0.38 | 0.16 | 5.43 | 1.45 | 1.16 | 2.17 | 0.020 | |
| Anti-CCP antibody positive, yes | −0.99 | 0.47 | 5.12 | 1.07 | 0.16 | 1.68 | 0.021 | |
| R2 | 0.379 | |||||||
OR odds ratio, CI confidence interval, DAS28-ESR Disease Activity Score in 28 joints-erythrocyte sedimentation rate, DMARDs disease-modifying antirheumatic drugs, RF rheumatoid factor, Anti-CCP anti-cyclic citrullinated peptide
Differences between patient-reported outcomes in patients with hand joint destruction compared to those without hand joint destruction
| Variables | Overall sample | Non-hand joint destruction (Sharp score = 0; | Hand joint destruction (Sharp score > 0; | z |
|
|---|---|---|---|---|---|
| HAQ-DI score (range 0–3), median (IQR) | 0.15 (0.88) | 0.05 (0.55) | 0.25 (1.26) | −3.62 | <0.001 |
| HADS-anxiety score (range 0–21), median (IQR) | 5 (3) | 5 (6) | 5 (5) | −0.57 | 0.571 |
| HADS-depression score (range 0–21), median (IQR) | 5 (5) | 3 (4.5) | 6 (6) | −1.50 | 0.047 |
| Domains of SF-36 scores (range 0–100), median (IQR) | |||||
| PCS | 37.75 (35.25) | 38 (32.75) | 36.63 (34.13) | −1.34 | 0.180 |
| MCS | 58.13 (35.13) | 59.63 (36.5) | 56.96 (34.22) | −0.80 | 0.423 |
| PF | 60 (47.5) | 65 (52.5) | 55 (55) | −2.50 | 0.012 |
| RP | 0 (25) | 0 (25) | 0 (25) | −0.22 | 0.830 |
| BP | 41 (43.5) | 52 (42) | 41 (51.5) | −0.78 | 0.434 |
| GH | 40 (32) | 42 (31.5) | 40 (30) | −1.44 | 0.106 |
| VT | 55 (20) | 55 (22.5) | 60 (20) | −0.32 | 0.752 |
| SF | 62.5 (50) | 62.5 (50) | 62.5 (46.88) | −1.26 | 0.208 |
| RE | 33.3 (100) | 66.7 (100) | 33.3 (100) | −0.32 | 0.752 |
| MH | 64 (24) | 68 (24) | 64 (24) | −0.30 | 0.761 |
IQR Interquartile range, HAQ-DI health assessment questionnaire-disability index, HADS Hospital Anxiety and Depression Scale, SF-36 Short Form 36 health survey, PCS physical components summary, MCS mental components summary, PF physical functioning, RP role physical, BP body pain, GH general health, VT vitality, SF social functioning, RE role emotional, MH mental health